Caribou Biosciences Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
CRBU$0.41-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Licensing and collaboration revenue (including $622 and $0, from a related party, respectively) | $2,429 | $3,502 |
| Operating expenses: | ||
| Research and development | 33,788 | 25,709 |
| General and administrative | 14,643 | 8,909 |
| Total operating expenses | 48,431 | 34,618 |
| Loss from operations | (46,002) | (31,116) |
| Other income (expense): | ||
| Change in fair value of equity securities | — | (15) |
| Change in fair value of the MSKCC success payments liability | 303 | 255 |
| Other income, net | 4,465 | 2,832 |
| Total other income | 4,768 | 3,072 |
| Net loss | (41,234) | (28,044) |
| Other comprehensive income (loss): | ||
| Net unrealized (loss) gain on available-for-sale marketable securities, net of tax | (352) | 788 |
| Net comprehensive loss | $(41,586) | $(27,256) |
| Net loss per share, basic and diluted | $(0.46) | $(0.46) |
| Weighted-average common shares outstanding, basic and diluted | 89,302,937 | 61,186,514 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.